Nano Nuclear Energy Inc
Filed Oct 21, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Oct 21, 2024
Contents
Cover page
Show cover page
As filed with** the U.S. Securities and Exchange Commission on October 21, 2024.**
Registration No. 333-[_______]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORMS-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NANO NUCLEAR ENERGY INC.
(Exact Name of Registrant as Specified in its Charter)
| Nevada | 4911 | 88-0861977 |
|---|---|---|
| (State or other jurisdiction of incorporation or organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification No.) |
10 Times Square**,30 th Floor**
New York, New York 10018
(212) 634-9206
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
James Walker
Chief Executive Officer
Nano Nuclear Energy Inc.
10 Times Square**,30 th Floor**
New York, New York 10018
(212) 634-9206
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
with copies to:
| Richard I Anslow, Esq. Lawrence A. Rosenbloom, Esq. Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas New York, NY 10105 Phone: (212) 370-1300 Fax: (212) 370-7889 | Joseph M. Lucosky, Esq. Scott E. Linsky, Esq. Lucosky Brookman LLP 101 Wood Avenue South, 5th Floor Woodbridge, NJ 08830 Tel. No.: (732) 395-4400 Fax No.: (732) 395-4401 |
|---|
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | Non-accelerated filer ☒ | Smaller reporting company ☒ |
|---|---|---|---|
| Emerging growth company ☒ | |||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.☐
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.
The information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
| PRELIMINARY PROSPECTUS | SUBJECT TO COMPLETION, DATED OCTOBER 21, 2024 |
|---|
1,398,602 Units consisting of 1,398,602** Shares of**
Common Stock and 2024 B
Warrants to Purchase up to 699,301 Shares of Common Stock
(and Shares of Common Stock issuable upon exercise of the 2024 B Warrants)
We are offering, on an underwritten, firm commitment basis, 1,398,602 units (the “Units”), with each Unit consisting of one (1) share of common stock and a 2024 B warrant to purchase up to one-half (0.5) of a share of common stock (the “Warrant”, or collectively, the “Warrants”) based on an assumed offering price of $21.45 per Unit, which was the last reported sale price of our common stock on the Nasdaq Capital Market (or Nasdaq) on October 16, 2024. We do not intend to apply for listing of the Warrants on any national securities exchange or other trading market, and we do not believe any such market will develop. Therefore, the liquidity of the Warrants will be limited and should be considered illiquid. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares of common stock and the Warrants underlying the Units are immediately separable and will be issued separately in this offering. The Warrants will have an exercise price of $[_____] per whole share and will be exercisable from the initial issuance date until they expire on the five-year anniversary of the original issuance date. The assumed offering price and related share numbers used throughout this prospectus have been included for illustration purposes only. The actual offering price may differ materially from the assumed price used in the prospectus and will be determined by negotiations between us and the representative of the underwriters and may not be indicative of prices that will prevail in the trading market.
This offering also relates to the shares of common stock issuable upon exercise of the Warrants sold in this offering. The shares of common stock can each be purchased in this offering only with the accompanying Warrants (other than pursuant to the underwriter’s warrant to purchase additional shares of common stock as part of the Units).
Our common stock is listed on Nasdaq under the symbol “NNE”. On October 16, 2024, the last reported sales price of a share of our common stock on Nasdaq was $21.45.
We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 and a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and, as such, may elect to comply with certain reduced public company reporting requirements for this prospectus and future filings. See “Summary — Implications of Being an Emerging Growth Company” and“Summary — Implications of Being a Smaller Reporting Company.”
Investing in our common stock is speculative and involves a high degree of risk. Before making any investment decision, you should carefully review and consider all the information in this prospectus,including the risks and uncertainties described under “Risk Factors” beginning on page 16.
Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| Per Unit | Total | ||
| Public offering price | $ | $ | |
|---|---|---|---|
| Underwriting discounts(1) | $ | $ | |
| Proceeds to us, before expenses(2) | $ | $ |
| (1) | Represents underwriting discounts equal to (i) seven percent (7%) per Unit (or $[_____] per Unit), which is the underwriting discounts we have agreed to pay to the underwriters. |
| (2) | Does not include a non-accountable expense allowance equal to one percent (1%) of the gross proceeds of this offering, payable to the representative of the underwriters, or the reimbursement of certain expenses of the underwriters. We have also agreed to issue warrants to the representative of the underwriters to purchase a number of shares of common stock equal to seven percent (7%) of the total number of shares of common stock included as part of the Units sold in this offering at an exercise price equal to one hundred and twenty-five percent (125%) of the public offering price of the Units sold in this offering. For a description of the other terms of compensation to be received by the underwriters, see “Underwriting.” |
We have granted a 30-day option to the representative of the underwriters to purchase up to an additional 209,790 shares of common stock and/or additional Warrants to purchase up to 104,895 shares of common stock solely to cover over-allotments, if any. If the representative of the underwriters exercises the option in full, the total underwriting discounts will be approximately $2,415,000 and the additional proceeds to us, before expenses, from the over-allotment option exercise will be approximately $4,140,000.
The underwriters expect to deliver the Units to purchasers on or about [●], 2024.
The Benchmark Company
The date of this prospectus is [●], 2024
Creating the Next Generation of Advanced Nuclear Fuels and Developing Smaller, Cheaper and Safer Portable Clean Energy Solutions
Renderings of proposed “Zeus” Microreactor
Renderings of proposed “Odin” Microreactor
Proposed HALEU Fuel Processing Facility
TABLE OF CONTENTS
| PAGE | |
|---|---|
| PROSPECTUS SUMMARY | 1 |
| THE OFFERING | 11 |
| SUMMARY OF CONSOLIDATED FINANCIAL INFORMATION | 13 |
| RISK FACTORS | 16 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS | 36 |
| USE OF PROCEEDS | 37 |
| DIVIDEND POLICY | 37 |
| CAPITALIZATION | 38 |
| DILUTION | 39 |
| MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 41 |
| BUSINESS | 49 |
| MANAGEMENT | 74 |
| EXECUTIVE AND DIRECTOR COMPENSATION | 84 |
| PRINCIPAL STOCKHOLDERS | 89 |
| CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS | 90 |
| DESCRIPTION OF CAPITAL STOCK | 92 |
| SHARES ELIGIBLE FOR FUTURE SALE | 98 |
| MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS | 100 |
| UNDERWRITING | 104 |
| LEGAL MATTERS | 108 |
| EXPERTS | 108 |
| WHERE YOU CAN FIND ADDITIONAL INFORMATION | 108 |
| INDEX TO FINANCIAL STATEMENTS | F-1 |
You should only rely on the information contained in this prospectus and in any free writing prospectus prepared by or on behalf of us and delivered or made available to you. Neither we nor the underwriters have authorized anyone to provide you with additional or different information. We are offering to sell, and seeking offers to buy, the Units only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or a free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of the Units offered hereby. Our business, financial condition, operating results, and prospects may have changed since that date.
For investors outside the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Units, and the distribution of this prospectus outside of the United States.
i
INDUSTRY AND MARKET DATA
Unless otherwise indicated, information in this prospectus concerning economic conditions, our industry, our markets and our competitive position is based on a variety of sources, including information from third-party industry analysts and publications and our own estimates and research. Some of the industry and market data contained in this prospectus are based on third-party industry publications. This information involves a number of assumptions, estimates and limitations.
The industry publications, surveys and forecasts and other public information generally indicate or suggest that their information has been obtained from sources believed to be reliable. None of the third-party industry publications used in this prospectus were prepared on our behalf. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors” in this prospectus. These and other factors could cause results to differ materially from those expressed in these publications.
TRADEMARKS
We own or have rights to trademarks or trade names that we use in connection with the operation of our businesses, our corporate names, logos and website names. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the ® or™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent possible under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’ trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by any other companies. All other trademarks are the property of their respective owners.
ii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.